Open AccessFTY720 enhances osteogenic differentiation of bone marrow mesenchymal stem cells in ovariectomized rats
Author(s) -
Chuang Huang,
Rui Ling,
FeiJiang Li,
ErCui Li,
Qichao Huang,
BaoGang Liu,
Yin Ding,
Song You
Publication year - 2016
Publication title -
molecular medicine reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.727
H-Index - 56
eISSN - 1791-3004
pISSN - 1791-2997
DOI - 10.3892/mmr.2016.5342
Subject(s) - ovariectomized rat , runx2 , mesenchymal stem cell , osteocalcin , endocrinology , medicine , alkaline phosphatase , osteoclast , bone resorption , bone marrow , chemistry , osteoporosis , biology , microbiology and biotechnology , hormone , biochemistry , receptor , enzyme
Sphingosine-1-phosphate and its structural analog FTY720 (fingolimod) are important in the inhibition of osteoclast differentiation and bone resorption, however, it remains unknown whether they enhance osteogenic differentiation of the bone marrow mesenchymal stem cells (BM‑MSCs). The present study investigated the effect of FTY720 on the osteogenic differentiation of BM‑MSCs from the femurs of the ovariectomized (OVX) rats. Three different concentrations (1, 10 and 100 nM) of FTY720 were demonstrated to markedly upregulate mRNA expression levels of Runt‑related transcription factor 2 (Runx2) and Sp7 transcription factor (Sp7) at 2 weeks, and alkaline phosphatase (ALP) at 3 weeks. The osteocalcin (OCN) expression was similar at weeks 2 and 3. The protein expression levels of Runx2, Sp7, OCN and ALP induced by three different concentrations of FTY720 were higher than those in the control groups at 3 weeks in the OVX and sham groups. The findings of the current study suggested a beneficial effect of FTY720 on bone formation in OVX rats, and provided a potential therapeutic method of FTY720 to prevent alveolar bone resorption in patients with post‑menopausal osteoporosis.